ASH 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2022 Conference Coverage

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical & Molecular Responses for Patients With R/R MM

By ASH 2022 Conference Coverage FEATURING Noopur S. Raje

0 views

December 22, 2022

Comments 0

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Myeloma